Stock 2256 ABBISKO CAYMAN LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Abbisko Cayman Limited

Equities

2256

KYG0028A1085

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
3.28 HKD +4.79% Intraday chart for Abbisko Cayman Limited +13.10% -10.14%
Apr. 25 Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation MT
Apr. 24 Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Abbisko Cayman's Liver Cancer Drug Gets US FDA Orphan Drug Designation
MT
Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary
CI
Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting
MT
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment
MT
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib
CI
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise
MT
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares
MT
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.
CI
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment
MT
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment
MT
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme
MT
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug
MT
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）
PR
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%
MT
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051
CI
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment
MT
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib
CI
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
PR
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2256 Stock
  4. News Abbisko Cayman Limited